

Company Overview

Silence Therapeutics' (AIM:SLN) proprietary short interfering RNA (siRNA) technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. RNAi-based therapies are considered to carry a lower risk of failure than traditional approaches as the biological effects are more predictable. During 2018 the first RNAi drug was approved, validating this exciting new modality. Silence is progressing several new drugs via its expanding pipeline, including SLN124 for iron overload disorders and also an unnamed cardiovascular drug. Cash at 30/06/18 was £34M.


Leadership Team

- **Dr David Horn Solomon**
Chief Executive Officer
- **David Ellam**
Chief Financial Officer
- **Linnea Elrington**
VP HR
- **Dr Richard Jenkins**
VP Clinical Devt.
- **Dr Marie Lindholm**
VP Tech Innovation
- **Mike Mulqueen**
VP Business Devt.
- **Dr Laura Roca-Alonso**
VP Corporate Devt.

Board of Directors

- **Dr David Horn Solomon**
Chief Executive Officer
- **David Ellam**
Chief Financial Officer
- **Dr Andy Richards CBE**
Interim Non-Executive Chair
- **Alistair Gray**
Non-Executive Director
- **Dave Lemus**
Non-Executive Director
- **Dr Stephen Parker**
Non-Executive Director

Silence Therapeutics pipeline



Silence's technology is highly specific, inhibiting disease-causing genes and allowing cells to revert to their original state. The technology enables rapid development and Silence can go from idea to "first in human" in 24 months. There is significant market potential for the lead candidate, SLN124 for Beta Thalassaemia, Myelodysplastic syndrome & other expansion opportunities including Haemochromatosis.

Investor Base

Silence Therapeutics has a global investor base including Invesco Perpetual Asset Management, Woodford Investment Management, Aviva Investors and ING Bank together with high net worth individuals.

Contact Information

United Kingdom:
72 Hammersmith Road,
London, W14 8TH

Germany:
Robert-Rössle-Str. 10
D-13125 Berlin, Germany

You can find more information by visiting our website www.silence-therapeutics.com or emailing silencetherapeutics@consilium-comms.com